Creating Bioentrepreneurs: Enterprise Specialisation Launch
Level 10, Woodward Conference Centre
185 Pelham Street, Carlton
'Having the informed attitude and skills to translate Australian medical research discoveries into economic and societal benefits will be key to the future success and contribution of our students.' Professor Andrew Cuthbertson, Chief Scientific Officer and R&D Director, CSL Limited.
Join us for a panel discussion about the need, and potential, for improved health and economic outcomes within an emerging local biomedical industry hub.
This free public event features leaders in biomedical research and enterprise, discussing the exciting potential for innovation and commercialisation both locally and internationally.
Keynote speaker Dr. Lynn Johnson Langer (Johns Hopkins University, USA) will present the Johns Hopkins experience: an eminent research institution embedded within the leading Maryland (USA) biotechnology cluster.
A key theme of Dr Johnson Langer's presentation will be Johns Hopkins' impact in developing commercially-skilled researchers that are bringing new biomedical discoveries to market.
A panel of experts from academia, industry and government will follow, discussing the need and potential for local biomedical professionals that possess research and enterprise talents - vital to translating discoveries into products and improving community health outcomes.
Delivered in collaboration with Melbourne Business School, Melbourne School of Engineering, the Wade Institute of Entrepreneurship and Johns Hopkins University (USA), Enterprise will prepare students to drive innovation within biomedical research and capitalise on the potential health and economic benefits of their discoveries.
Morning tea and a light lunch will be served. Bookings essential.
Professor Fabienne Mackay, Head of School of Biomedical Sciences
Professor Fabienne Mackay
Head of School of Biomedical Sciences
Faculty of Medicine, Dentistry and Health Sciences
Professor Fabienne Mackay obtained her PhD from Louis Pasteur University in Strasbourg, France. In 1994, she joined BiogenIdec Inc in Boston where she developed inhibitors of TNF ligands and characterised the factor BAFF. In 2000, Fabienne joined the Garvan Institute, Sydney as a Wellcome Trust Senior Research Fellow with a National Health and Medical Research Council (NHMRC) Program Grant and as Director of the Autoimmunity Research Unit. In 2009, Fabienne was appointed Chair and Head, Department of Immunology, Monash University. In 2012, Prof Mackay received the Thomson Reuters Australia citation and innovation award; 2013 awarded NHMRC Best Research Project; 2014 received a trophy from the French Ministry of Foreign Affairs in Paris for outstanding contribution in education and research as an expatriate; and 2015 was elected as Council Member of the International Cytokine & Interferon Society. In 2015, she joined the University of Melbourne as inaugural Head, School of Biomedical Sciences in the Faculty of Medicine, Dentistry and Health Sciences and Head, BAFF laboratory, Department of Microbiology and Immunology.
Dr Lynn Johnson Langer, Director of Enterprise, Entrepreneurship and International Programs, Advanced Academic Programs
Dr Lynn Johnson Langer
Director of Enterprise, Entrepreneurship and International Programs, Advanced Academic Programs
Johns Hopkins University
Lynn Johnson Langer PhD, MBA, is Director of Enterprise, Entrepreneurship and International Programs, which includes the Masters in Biotechnology Enterprise and Entrepreneurship (MBEE), the MS in Biotechnology/MBA, the MS in Biotechnology (Enterprise concentration), and the Certificate in Biotechnology Enterprise. Dr. Langer is on the National Directors Emeritus board and is President Emeritus of Women In Bio, an organization of professionals committed to fostering and encouraging entrepreneurship and career development of women active in the life science industry. She recently ended her governorappointed term on the board of directors of the Maryland Technology Development Corporation. She attended Tulane University and the University of Maryland for her undergraduate degree in microbiology. She later received her MBA from Johns Hopkins University and received the Stegman Award for academic excellence in Administrative Science. She received her PhD in Leadership and Change from Antioch University. Dr. Langer is also an International Coach Federation certified executive coach. She studied coaching at George Washington University and completed a graduate certificate in evidencebased coaching from the Fielding Graduate Institute. Dr. Langer headed the sales and marketing department of several biotechnology companies before she founded BioPlan Associates, a management and marketing consulting firm. She has published over fifty articles and several book chapters mainly in business areas of biotechnology and biotechnology enterprise education including publishing in Nature Biotechnology. Dr. Langer has taught a variety of graduate courses in biotechnology and business.
Professor Andrew Cuthbertson, Chief Scientific Officer and R&D Director
Professor Andrew Cuthbertson
Chief Scientific Officer and R&D Director
After completing medical training at the University of Melbourne and Ph.D in Immunology at the Walter and Eliza Hall Institute in Australia, Andrew Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne and the National Institutes of Health in the United States. He then spent seven years at Genentech Inc. in San Francisco, working on anti–VEGF therapy for agerelated macular degeneration. Andrew was recruited to CSL Limited in 1997 and is the R&D Director and Chief Scientific Officer of CSL Limited. In 2016, he was made an Enterprise Professor, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne and an Officer of the Order of Australia for his services to medical research. Andrew has a keen interest in biopharmaceutical drug development. He currently manages an internal R&D budget of over US$600m, and a global R&D organisation of over 1,400 scientists. He is responsible for crafting the global R&D strategy for CSL.
Dr Amanda Caples, Lead Scientist
Dr Amanda Caples
Dr Amanda Caples BSc Hons PhD GAICD was appointed to the Victorian Lead Scientist role in mid2016. The Lead Scientist works across the Victorian Government to foster linkages and identify opportunities for economic outcomes by engaging with business, the research sector and the Australian government. Amanda brings to the role broad experience in technology commercialisation, public policy development and governance of public and private entities. Previously as Deputy Secretary Sector Development and Programs, Amanda was responsible for the development of Future Industries strategic sector growth plans and for support of the Victorian science, innovation and entrepreneurial ecosystem. Amanda joined the Victorian public service in 2002 as the inaugural Director of Biotechnology and subsequently was appointed as the Executive Director Science and Technology to drive the state’s science agenda. In these roles, Amanda has led the development of industry sector strategy plans, delivered researchled health initiatives, regulatory and legislative scientific reforms and established international business development and research alliances. In these roles, Amanda has worked with Commonwealth agencies on national science and innovation policies and programs, including the Australian Synchrotron and the National Collaborative Research Infrastructure Scheme.
Dr Shane Huntington, Principal Strategy Adviser to the Dean of MDHS and Host of 3RRR’s science program, 'Einstein a Go Go'.
Dr Shane Huntington
Principal Strategy Adviser to the Dean of MDHS and Host of 3RRR’s science program, 'Einstein a Go Go'.
Faculty of Medicine, Dentistry and Health Sciences
Dr Shane Huntington is the Principal Strategy Adviser to the Dean of the Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne In Addition Dr Huntington is a Founder and the Managing Director of The Innovation Group Pty Ltd, a Victorian based company set up in 2000 to assist with the commercialisation of Victorian research and technology. In 2000 and 2001, in collaboration with The City of Melbourne, The State Government of Victoria (OST), and AusIndustry, The Innovation Group ran extensive workshop programs on commercialisation. In 2002, Dr Huntington initiated substantial changes to the business plan of the company, evolving its principle focus towards the supply of scientific and industrial instruments. The Innovation Group currently represents six international technology companies in Australia and New Zealand. For the past 19 years, Dr Huntington has been a broadcaster on 3RRR’s science radio program. In this capacity he has interviewed more than 500 scientists and provided detailed descriptions of hundreds of scientific concepts to a general audience. He is also currently the Science and Engineering host of Melbourne University’s Upclose podcasting program. Until March 2008 he was the CEO of Quantum Communications Victoria within the School of Physics at the University of Melbourne. Quantum Communications Victoria is a $9.3Million Government funded program which aims to make Australia a leader in telecommunications security based on Quantum Physics. Shane has a PhD in Physics, with a specialty in Photonics and Imaging.
Dr C. Glenn Begley, Chief Executive Officer, BioCurate
Dr C. Glenn Begley
Chief Executive Officer, BioCurate
BioCurate Pty Ltd
Dr C. Glenn Begley is a clinical haematologist and medical oncologist, whose academic and commercial roles include board level and senior positions in Australia, the USA and the UK. Prior to joining BioCurate, Dr Begley held the position of Chief Scientific Officer at Akriveia Therapeutics (Califormia), Chief Scientific Officer at TetraLogic Pharmaceuticals (Pennsylvania) and , from 20022012, VicePresident and Global Head of Hematology/Oncology Research at Amgen. During this time, he became interested in the issue of research integrity and scientific reproducibility. Before joining Amgen, Dr Begley had over 20 years of clinical experience in medical oncology and hematology. His personal research focused on regulation of hematopoietic cells and translational clinical trials. Dr Begley studied Medicine at undergraduate and postgraduate level at The University of Melbourne.